Q1 2018 Earnings Forecast for Quotient Ltd Issued By Jefferies Group (QTNT)
Quotient Ltd (NASDAQ:QTNT) – Investment analysts at Jefferies Group lifted their Q1 2018 earnings per share estimates for Quotient in a report released on Tuesday. Jefferies Group analyst B. Couillard now anticipates that the company will earn ($0.56) per share for the quarter, up from their prior estimate of ($0.72). Jefferies Group also issued estimates for Quotient’s Q2 2018 earnings at ($0.57) EPS, Q3 2018 earnings at ($0.34) EPS, Q4 2018 earnings at ($0.54) EPS, FY2018 earnings at ($2.00) EPS and FY2019 earnings at ($1.10) EPS.
Quotient (NASDAQ:QTNT) last announced its quarterly earnings results on Monday, May 22nd. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.07. The business had revenue of $5.53 million for the quarter, compared to analysts’ expectations of $4.30 million. Quotient had a negative return on equity of 306.53% and a negative net margin of 341.53%. COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/05/27/q1-2018-earnings-forecast-for-quotient-ltd-issued-by-jefferies-group-qtnt.html.
QTNT has been the topic of a number of other reports. Zacks Investment Research downgraded Quotient from a “hold” rating to a “sell” rating in a research report on Friday, February 3rd. BTIG Research reaffirmed a “buy” rating and set a $22.00 price objective on shares of Quotient in a report on Tuesday, April 18th.
Shares of Quotient (NASDAQ:QTNT) opened at 7.56 on Thursday. Quotient has a 12 month low of $3.75 and a 12 month high of $12.96. The stock’s 50 day moving average price is $6.94 and its 200-day moving average price is $6.04. The firm’s market capitalization is $108.68 million.
A number of large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in Quotient by 29.3% in the first quarter. Geode Capital Management LLC now owns 16,066 shares of the company’s stock worth $112,000 after buying an additional 3,643 shares during the last quarter. Nicholas Hoffman & Company LLC. bought a new stake in Quotient during the first quarter worth $150,000. FNY Partners Fund LP bought a new stake in Quotient during the first quarter worth $636,000. Park West Asset Management LLC increased its stake in Quotient by 8.0% in the third quarter. Park West Asset Management LLC now owns 270,034 shares of the company’s stock worth $2,112,000 after buying an additional 20,034 shares during the last quarter. Finally, BlackRock Group LTD increased its stake in Quotient by 6.6% in the third quarter. BlackRock Group LTD now owns 283,423 shares of the company’s stock worth $2,216,000 after buying an additional 17,465 shares during the last quarter. 48.99% of the stock is currently owned by institutional investors.
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Stock Ratings for Quotient Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Ltd and related stocks with our FREE daily email newsletter.